OLMA Live signaler | Maksimer profitt med Getagraph.com

KJøP 108922 min ago

@ $15.41

Utstedt: 14 feb 2024 @ 17:19

Avkastning: -34.07%

Forrige signal: feb 14 - 15:30

Forrige signal: Selg

Avkastning: -3.51 %

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 22:00):

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers...

Stats
Dagens volum	332 566
Gjennomsnittsvolum	831 451
Markedsverdi	568.09M
EPS	$0 ( 2024-03-14 )
Neste inntjeningsdato	( $-0.530 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.75
ATR14	$0.0190 (0.19%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Harmon Cyrus	Sell	20 000	Common Stock
2024-03-18	Zojwalla Naseem	Sell	13 700	Stock Option (Right to Buy)
2024-03-18	Zojwalla Naseem	Buy	13 700	Common Stock
2024-03-05	Rappaport Andrew	Buy	385 965	Common Stock
2024-03-05	Rappaport Andrew	Sell	481 014	Common Stock

INSIDER POWER
66.24
Last 96 transactions
Buy: 6 282 820 \| Sell: 988 788

Volum Korrelasjon

Lang: -0.06 (neutral)

Kort: -0.46 (neutral)

Signal:(72.527) Neutral

Olema Pharmaceuticals, Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Olema Pharmaceuticals, Korrelasjon - Valuta/Råvare

-0.79
( moderate negative )

-0.86
( strong negative )

0.00
( neutral )

-0.82
( strong negative )

-0.33
( neutral )

0.48
( neutral )

Olema Pharmaceuticals, Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-377 000 (0.00 %)
EPS:	$-2.14

FY	2023
Omsetning:	$0
Bruttogevinst:	$-377 000 (0.00 %)
EPS:	$-2.14

FY	2022
Omsetning:	$0
Bruttogevinst:	$-1.66M (0.00 %)
EPS:	$-2.56

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.795

Financial Reports:

No articles found.

Olema Pharmaceuticals,

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.